Non-pharmaceutical factors for poor glycemic control in 13,970 Chinese women with drug-treated type 2 diabetes: a cross-sectional survey in 77 tertiary hospitals in four Chinese cities
Authors Lu JL, Weng J, Gu W, Guo X, Yang W, Zou D, Zhou Z, Zhu D, Ji Q, Ji L, Yang X
Received 28 April 2014
Accepted for publication 27 June 2014
Published 30 August 2014 Volume 2014:8 Pages 1161—1167
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Juming Lu,1,* Jianping Weng,2,* Weijun Gu,1 Xiaohui Guo,3 Wenying Yang,4 Dajin Zou,5 Zhiguang Zhou,6 Dalong Zhu,7 Qiuhe Ji,8 Linong Ji,9 Xilin Yang10
1Department of Endocrinology, Chinese PLA General Hospital, Beijing, 2Department of Endocrinology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 3Department of Endocrinology, First Hospital of Peking University, Beijing, 4Department of Endocrinology, Sino-Japan Friendship Hospital, Beijing, 5Department of Endocrinology, Changhai Hospital of Shanghai, Shanghai, 6Department of Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, 7Department of Endocrinology, Nanjing Drum Tower Hospital, Nanjing, Jiansu, 8Department of Endocrinology, Xijing Hospital affiliated to 4th Military Medical University, Xi’an, 9Department of Endocrinology, Peking University People’s Hospital, Beijing, 10Department of Epidemiology and Biostatistics, School of Public Health, Tianjin Medical University, Tianjin, People’s Republic of China
*These authors contributed equally to the manuscript
Background: Achieving good glycemic control improves clinical outcomes among patients with type 2 diabetes (T2D). This study aimed to explore non-pharmaceutical factors for poor glycemic control in Chinese women with T2D who used antidiabetic drug(s).
Methods: A cross-sectional survey was conducted in March to June 2011 in 77 top tertiary hospitals in Beijing, Shanghai, Tianjin, and Guangzhou, People’s Republic of China (the coverage rates of the 3A hospitals: 74.4%, 76%, 55%, and 29.3%, respectively). Of 29,502 patients with T2D who used oral antidiabetic drugs (OADs) alone or combined with insulin, 13,970 were women and used in the analysis. Logistic regression analysis was used to obtain odds ratios (ORs) and 95% confidence intervals (CIs) of factors for hyperglycemia defined as HbA1c (glycated hemoglobin) ≥77 mmol/mol (7.0%).
Results: The mean age was 60.3 (standard deviation 11.0) years, with a median of 4 (interquartile range 2–9) years of duration of diabetes, and 65.1% had hyperglycemia. In multivariable analysis, body height of ≥164 cm (OR 1.26, 95% CI 1.15–1.37) and obesity (OR 1.16, 95% CI 1.04–1.31) was associated with increased risk of hyperglycemia, while self-monitoring blood glucose (SMBG) decreased the risk of hyperglycemia (OR 0.78, 95% CI 0.73–0.84). Duration of diabetes ≥3 years (≥3 to <6 years, OR 1.46, 95% CI 1.32–1.62; ≥6 to <10 years, OR 1.65, 95% CI 1.44–1.89), especially ≥10 years (OR 1.95, 95% CI 1.73–2.19), was associated with higher risks of hyperglycemia.
Conclusion: Body height ≥164 cm, obesity, and duration of diabetes ≥3 years increased while SMBG decreased risk of hyperglycemia in Chinese women with OAD-treated T2D.
Keywords: HbA1c goal, hyperglycemia, oral antidiabetic drugs
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]